BR112017012272A2 - derivados de 2-anilinopirimidina como moduladores de egfr - Google Patents

derivados de 2-anilinopirimidina como moduladores de egfr

Info

Publication number
BR112017012272A2
BR112017012272A2 BR112017012272-3A BR112017012272A BR112017012272A2 BR 112017012272 A2 BR112017012272 A2 BR 112017012272A2 BR 112017012272 A BR112017012272 A BR 112017012272A BR 112017012272 A2 BR112017012272 A2 BR 112017012272A2
Authority
BR
Brazil
Prior art keywords
anilinopyrimidine derivatives
egfr modulators
egfr
anilinopyrimidine
derivatives
Prior art date
Application number
BR112017012272-3A
Other languages
English (en)
Inventor
Peng
JiRong
Costanzo
Michael
John
Greco
Nicholas
Green
Alan
Wilde
Victoria
Lynn
Zhang
Don
Original Assignee
Beta Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma, Inc. filed Critical Beta Pharma, Inc.
Publication of BR112017012272A2 publication Critical patent/BR112017012272A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

a presente invenção refere-se a novos derivados 2-anilinopirimidina substituídos e seus sais, solvatos, prodrogras e composições que são úteis para o tratamento ou prevenção de doenças ou condições médicas mediadas pelos receptores de fator de crescimento epidérmico (egfr), que incluem, mas não se limitam a uma variedade de tipos de câncer.
BR112017012272-3A 2014-12-11 2015-12-11 derivados de 2-anilinopirimidina como moduladores de egfr BR112017012272A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462090869P 2014-12-11 2014-12-11
US62/090,869 2014-12-11
US201562166883P 2015-05-27 2015-05-27
US62/166,883 2015-05-27
PCT/US2015/065286 WO2016094821A2 (en) 2014-12-11 2015-12-11 Substituted 2-anilinopyrimidine derivatives as egfr modulators

Publications (1)

Publication Number Publication Date
BR112017012272A2 true BR112017012272A2 (pt) 2018-01-30

Family

ID=56108380

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017012272-3A BR112017012272A2 (pt) 2014-12-11 2015-12-11 derivados de 2-anilinopirimidina como moduladores de egfr

Country Status (17)

Country Link
US (2) US10590111B2 (pt)
EP (1) EP3229798A4 (pt)
JP (2) JP6709786B2 (pt)
KR (1) KR20170098865A (pt)
CN (3) CN112457298A (pt)
AU (1) AU2015360360B2 (pt)
BR (1) BR112017012272A2 (pt)
CA (1) CA2970185C (pt)
CO (1) CO2017006962A2 (pt)
EA (1) EA036453B1 (pt)
HK (1) HK1245634A1 (pt)
IL (1) IL252554A0 (pt)
MX (1) MX2017007664A (pt)
PH (1) PH12017501057A1 (pt)
SG (2) SG10201909060SA (pt)
TW (1) TWI618704B (pt)
WO (1) WO2016094821A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CA2970185C (en) * 2014-12-11 2023-10-17 Beta Pharma, Inc. Substituted 2-anilinopyrimidine derivatives as egfr modulators
AU2017264839B2 (en) 2016-05-11 2021-08-05 Beta Pharma, Inc. 2-Anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
AU2017269335B2 (en) 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
US10844045B2 (en) * 2016-06-17 2020-11-24 Beta Pharma, Inc. Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
CN106243044A (zh) * 2016-06-30 2016-12-21 浙江大学 含卤代丙烯酰胺侧链的嘧啶类衍生物及制备和应用
CN110818690B (zh) 2016-07-26 2021-08-10 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
EA201992744A1 (ru) 2017-06-16 2020-05-27 Бета Фарма, Инк. Фармацевтические композиции n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и его солей
CN109503573A (zh) * 2017-09-14 2019-03-22 昆明圣加南生物科技有限公司 2-取代苯胺基嘧啶衍生物及其用途
CN107935995A (zh) * 2017-11-28 2018-04-20 中山大学 一种新型2‑苯胺基嘧啶衍生物及其在制备抗肿瘤药物中的应用
CN108017633A (zh) * 2018-01-30 2018-05-11 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
CN112533632A (zh) * 2018-06-18 2021-03-19 Ucb生物制药有限责任公司 用于预防和治疗癌症的gremlin-1拮抗剂
TW202126305A (zh) * 2019-09-23 2021-07-16 美商貝達醫藥公司 使用egfr及cdk4/6抑制劑之組合以治療egfr突變體相關癌症
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
MX2022008874A (es) 2020-01-20 2022-08-11 Astrazeneca Ab Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TW202317578A (zh) * 2021-07-13 2023-05-01 開曼群島商艾森醫藥有限公司 雜環化合物及其用途
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2699568C (en) * 1999-12-24 2013-03-12 Aventis Pharma Limited Azaindoles
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
CA2670375A1 (en) * 2006-12-08 2008-06-12 F. Hoffmann-La Roche Ag Substituted pyrimidines and their use as jnk modulators
US8349898B2 (en) * 2008-11-18 2013-01-08 Wisconsin Alumni Research Foundation Sigma-1 receptor ligands and methods of use
US9908884B2 (en) * 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
WO2012151561A1 (en) * 2011-05-04 2012-11-08 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN104109161B (zh) * 2011-07-27 2016-08-17 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
WO2013169401A1 (en) * 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
AP2017009690A0 (en) * 2014-06-19 2017-01-31 Ariad Pharma Inc Heteroaryl compounds for kinase inhibition
CN113121575A (zh) * 2014-08-25 2021-07-16 四川海思科制药有限公司 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
CN105461695B (zh) * 2014-09-29 2018-03-27 齐鲁制药有限公司 嘧啶或三嗪衍生物及其制备方法和用途
CN111170998B (zh) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CA2970185C (en) 2014-12-11 2023-10-17 Beta Pharma, Inc. Substituted 2-anilinopyrimidine derivatives as egfr modulators

Also Published As

Publication number Publication date
KR20170098865A (ko) 2017-08-30
CN112375067B (zh) 2024-03-15
US20170362203A1 (en) 2017-12-21
MX2017007664A (es) 2018-01-23
CN108024993B (zh) 2020-11-06
CA2970185A1 (en) 2016-06-16
SG11201704685TA (en) 2017-07-28
JP7181558B2 (ja) 2022-12-01
CO2017006962A2 (es) 2017-10-20
SG10201909060SA (en) 2019-11-28
AU2015360360A1 (en) 2017-06-08
TWI618704B (zh) 2018-03-21
AU2015360360B2 (en) 2020-06-25
CN112457298A (zh) 2021-03-09
TW201632512A (zh) 2016-09-16
CN108024993A (zh) 2018-05-11
WO2016094821A3 (en) 2016-08-25
US11414401B2 (en) 2022-08-16
EA201790921A1 (ru) 2017-12-29
IL252554A0 (en) 2017-07-31
PH12017501057A1 (en) 2018-03-05
JP6709786B2 (ja) 2020-06-17
US20200216421A1 (en) 2020-07-09
JP2020143131A (ja) 2020-09-10
EA036453B1 (ru) 2020-11-12
HK1245634A1 (zh) 2018-08-31
CA2970185C (en) 2023-10-17
WO2016094821A2 (en) 2016-06-16
EP3229798A4 (en) 2018-05-30
JP2017537114A (ja) 2017-12-14
EP3229798A2 (en) 2017-10-18
CN112375067A (zh) 2021-02-19
US10590111B2 (en) 2020-03-17

Similar Documents

Publication Publication Date Title
BR112017012272A2 (pt) derivados de 2-anilinopirimidina como moduladores de egfr
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
MX2020001278A (es) Sintesis de compuestos de carbamoilpiridona policiclica.
MX2018001032A (es) Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr.
DOP2018000008A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CO2017004074A2 (es) Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
ECSP16074207A (es) Pirazinas moduladoras de gpr6
BR112016024484A2 (pt) derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
TN2016000177A1 (en) P-substituted asymmetric ureas and medical uses thereof
DOP2017000196A (es) Derivados de tetrahidropiranil benzamida
ECSP17046657A (es) Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam
BR112018005377A2 (pt) método para preparar uma formulação estável
BR112017018992A2 (pt) processo de preparação de derivados de fenilisoxazolina substituída

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.